Biliary excretion of organic anions, such as bile acids (BAs), is the main osmotic driving force for bile formation, and its impairment induces intrahepatic cholestasis. We investigated the involvement of Atp11c in the hepatic transport of organic anions using Atp11c mutant mice, which exhibit hypercholanemia and hyperbilirubinemia. Pharmacokinetic analysis following a constant intravenous infusion in Atp11c mutant mice showed decreased hepatic sinusoidal uptake and intact biliary secretion of [ 3 H]17b estradiol 17b-D-glucuronide. Consistent with this result, compared with cells and membranes from control mice, isolated hepatocytes, and liver plasma membranes from Atp11c mutant mice had a much lower uptake of [ 3 H]17b estradiol 17b-Dglucuronide and expression of organic anion-transporting polypeptides, which are transporters responsible for hepatic uptake of unconjugated BAs and organic anions, including bilirubin glucuronides. Uptake of [ 3 H]TC into hepatocytes and expression of Na 1 -taurocholate cotransporting polypeptide in liver plasma membranes, which mediates hepatic uptake of conjugated BAs, was also lower in the Atp11c mutant mice. Bile flow rate, biliary BA concentration, and expression of hepatobiliary transporters did not differ between Atp11c mutant mice and control mice. These results suggest that Atp11c mediates the transport of BAs and organic anions across the sinusoidal membrane, but not the canalicular membrane, by regulating the abundance of transporters. Atp11c is a candidate gene for genetically undiagnosed cases of hypercholanemia and hyperbilirubinemia, but not of intrahepatic cholestasis. This gene may influence the pharmacological and adverse effect of drugs because organic anion-transporting polypeptides regulate their systemic exposure.
Introduction
The biliary excretion of bile acids (BAs) and glutathione from the hepatocyte is the main osmotic driving force for bile formation. Transport of BAs across the sinusoidal membrane is mediated by uptake transporters, Na 1 -taurocholate cotransporting polypeptide (in humans, NTCP; in rodents, Ntcp) (Hagenbuch et al., 1991; Hagenbuch and Meier, 1994) , and organic anion transporting polypeptides (in humans, OATPs; in rodents, Oatps) Trauner and Boyer, 2003) . After reaching the canalicular membrane (CM), monovalent taurine-and glycine-conjugated BAs [such as taurocholic acid (TC)] and sulfated BAs, such as amidates and bile salt ethereal glucuronides (divalent), are secreted into bile by the bile salt export pump (in humans, BSEP; in rodents, Bsep) (Gerloff et al., 1998; Byrne et al., 2002; Noe et al., 2002; Hayashi et al., 2005b ) and the multidrug resistance-associated protein (in humans, MRP; in rodents, Mrp) 2 (Kuipers et al., 1988; Takikawa et al., 1991; Akita et al., 2001 ), respectively, both of which are ATP-binding cassette transmembrane transporters located on the CM. Impaired transport of BAs across the CM causes intrahepatic cholestasis, a state of reduced bile flow that is an acquired or inherited syndrome, and results in hepatocellular damage because a high concentration of BAs is toxic. One of the most severe forms of intrahepatic cholestasis is progressive familial intrahepatic cholestasis (PFIC), a heterogeneous group of inherited autosomal recessive liver diseases. This group of diseases is characterized by intrahepatic cholestasis and jaundice in the first year of life and progression to severe cholestasis with sustained intractable itching, jaundice, watery diarrhea, and failure to thrive, which eventually leads to liver failure and death before adulthood (Davit-Spraul et al., 2009; Morotti et al., 2011) . PFIC is subdivided based on the serum gamma-glutamyl transferase (GGT) level and the causal genes (Davit-Spraul et al., 2009 ). ATP8B1 and ABCB11 have been identified as the genes responsible for PFIC associated with a normal GGT level Strautnieks et al., 1998) . However, about one-third of affected individuals with a normal GGT level have no mutations in either gene (Davit-Spraul et al., 2010) . In PFIC patients with mutations in ABCB11 encoding BSEP, biliary BA secretion is impaired because of the compromised expression of BSEP and/or abolished transport activity of BSEP (Wang et al., 2002; Hayashi et al., 2005a) . ATP8B1/Atp8b1 is a member of the P4 subfamily of P-type adenosine triphosphatases (P4-ATPases) and translocates the aminophospholipid from the outer leaflet to the inner leaflet in the lipid bilayer of biologic membranes (Paulusma et al., 2008; Ray et al., 2010; Takatsu et al., 2014) . It has been suggested that a deficiency in ATP8B1 causes secondary suppression of BSEP-mediated BA excretion into bile by disrupting the well organized aminophospholipid asymmetry in the CM (Paulusma et al., 2006 (Paulusma et al., , 2009 or through mass action related to the decreased expression of BSEP mRNA (Chen et al., 2004) .
Considering these underlying mechanisms, we have begun to search for agents that have therapeutic potency in patients with mutations in ATP8B1 and ABCB11. We have published experimental and clinical evidence that 4-phenylbutyrate, a drug used to treat ornithine transcarbamylase deficiency, has an additional pharmacological effect that increases the expression of BSEP on the CM (Hayashi and Sugiyama, 2007) and improves liver function and/or pruritus in these PFIC patients (Hasegawa et al., 2014; Naoi et al., 2014) . The development of therapeutic methods to treat other PFIC patients and understanding of the mechanism underlying intrahepatic cholestasis caused by inherited genetic defects require the identification of other genes that are causally associated with PFIC in the remaining 30% of patients with a normal GGT level.
Recently, two independent groups have constructed mutant mice that have inherited an N-ethyl-N-nitrosourea-induced point mutation in Atp11c (Siggs et al., 2011a; Yabas et al., 2011) that encodes a P4-type ATPase and functions as an aminophospholipid flippase (Yabas et al., 2011; Segawa et al., 2014; Takatsu et al., 2014) . These mutant mice developed cellintrinsic arrest of adult B lymphopoiesis and presented with anemia and hyperbilirubinemia (Siggs et al., 2011a; Yabas et al., 2011 Yabas et al., , 2014 . Subsequent detailed analysis of hyperbilirubinemia involving bone marrow transplantation and biochemical testing indicated that the hyperbilirubinemia derived from a deficiency in the function of Atp11c in nonhematopoietic cells. Atp11c mutant mice showed elevated total plasma BA and bilirubin levels, but a normal GGT level, compared with control mice (Siggs et al., 2011b) . Considering that Atp11c is expressed predominantly in the liver (Siggs et al., 2011b) , in the present study, we used Atp11c mutant mice to examine whether ATP11C could be the causal gene of PFIC associated with a normal GGT level. (Santa Cruz, CA) . Antisera to Mrp3, Oatp1b2, and Oatp1a4 were raised in rabbits as described previously (Hirohashi et al., 2000; Sasaki et al., 2004; Ose et al., 2010) . All other chemicals were of analytical grade.
Mice. The mouse strain with an Atp11c emptyhive allele, which contains an X-linked N-ethyl-N-nitrosourea-induced point mutation in Atp11c on a pure C57BL/6J background (C57BL/6J-Atp11c m1Btlr / Mmjax) (Siggs et al., 2011a,b) ). At 9-14 weeks of age, the mice were fasted for 12 hours and used for the experiments.
Genotyping of offspring was performed using genomic DNA isolated from tail biopsies. The Atp11c emptyhive allele has a 2113C.T mutation in Atp11c that confers resistance to restriction by MboI to Atp11c. A partial sequence (359 base pairs) of Atp11c, which included the mutated sites in the Atp11c emptyhive allele, was amplified using polymerase chain reaction (PCR) involving 59-TGAGCTACAGCACT-CAGCAGC-39 (forward) and 59-TTGGAAAAGGCGGCAGGCATAGC-39 (reverse) as primers. The samples were digested by MboI for 1 hour at 37°C and analyzed by electrophoresis. The products from male control (Atp11c 1/Y ) mice and female control (Atp11c 1/1 ) mice were digested into two bands of 242 and 117 base pairs, whereas those from male hemizygous (Atp11c (Fig. 1A) . All three bands were observed in the products from female heterozygous (Atp11c 1/emptyhive ) mice. All animals were maintained under standard conditions with a reversed dark/light cycle and treated humanely. Food and water were available ad libitum. The studies reported in this manuscript were carried out in accordance with the guidelines provided by the Institutional Animal Care Committee (Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan).
Analysis of Serum, Liver, and Bile Composition. Biochemical testing of serum was outsourced to the Oriental Yeast Co. (Tokyo, Japan). Lipids and BAs were extracted from the serum, liver, and bile using the Bligh-Dyer method (Bligh and Dyer, 1959) and then subjected to enzymatic measurement of BA concentration (Wako Pure Chemical Industries, Tokyo, Japan).
In Vivo Infusion Study in Mice. Male mice (9-14 weeks old) were fasted for 12 hours and then subjected to an in vivo infusion study using [ 3 H]TC and [ 3 H]E 2 17bG as described (Hirano et al., 2005; Hayashi and Sugiyama, 2007; Hayashi et al., 2012b H]E 2 17bG in saline was infused through the jugular vein cannula at a rate of 500 and 13.3 pmol/min per kg for 60 minutes, respectively. Blood and bile specimens were obtained at specified times. The radioactivity associated with the plasma, bile, and liver was measured in a liquid scintillation counter (LS 600SC; Beckman, Fullerton, CA) as described previously (Hayashi and Sugiyama, 2007; Hayashi et al., 2012b) .
Pharmacokinetic Analysis. The total plasma clearance (CL total ), biliary clearance normalized by circulating plasma concentration (CL bile, plasma ), and biliary clearance normalized by the liver concentration (CL bile, liver ) were calculated from the equations CL total 5 I/C ss, plasma , CL bile, plasma 5 V ss, bile /C ss, plasma , and CL bile, liver 5 V ss, bile /C ss, liver , respectively, where I represents the infusion rate (pmol/min per kg), C ss, plasma represents the steady-state plasma concentrations (nM), V ss, bile represents the steady-state biliary excretion rate (pmol/min per kg), and C ss, liver represents the average steady-state hepatic concentration (pmol/g liver) (Hayashi and Sugiyama, 2007; Hayashi et al., 2012b (Yamazaki et al., 1993) , suspended in Krebs-Henseleit buffer, and adjusted to 2.0 Â 10 6 cells/ml. The hepatocyte suspensions were prewarmed at 37°C for 3 minutes and then subjected to the uptake assay as described previously (Hirano et al., 2004 Western Blot Analysis. Liver plasma membranes (LPMs) were prepared from Atp11c 1/Y and Atp11c emptyhive/Y mice, loaded to the wells of 7 or 10% SDS-PAGE gel with a 3.75% stacking gel, and then subjected to Western blot analysis as described previously (Hayashi and Sugiyama, 2007; Hayashi et al., 2012a,b; Mizuno et al., 2015) . Immunoreactivity was detected with an ECL Prime Western Blotting Detection Reagent (Amersham Biosciences, Piscataway, NJ). The intensity of the band indicating each protein was quantified using Multi Gauge software (version 2.0; Fujifilm, Tokyo, Japan).
Determination of mRNA Levels. Total RNA from the liver specimens of mice was isolated using ISOGEN II (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. Reverse transcription was performed with ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo, Tokyo, Japan). The mRNA level for each protein were measured by real-time quantitative PCR using the LightCycler 480 System II (Roche Diagnostics, Mannheim, Germany) as described previously (Hayashi and Sugiyama, 2007; Hayashi et al., 2012b; Naoi et al., 2014) . The following primer sequences were used: 59-CTGTCATCAATGTGGGCAAC-39 (forward) and 59-CTGTTTCCAT GCTGATGGTG-39 (reverse) for Ntcp; 59-TAGCTTGCCTCCAGTAT GCCTT-39 (forward) and 59-ACAGGCCAAATGCTATGTATGC-39 and Atp11c emptyhive/Y mice, cut into small pieces, embedded in the Optimal Cutting Temperature compound (Sakura Finetek, Torrance, CA), and frozen in liquid nitrogen. Ten-micrometer-thick sections were prepared from the frozen sections using a cryostat (Leica CM 1950; Leica, Solms, Germany), mounted onto cover glasses (Matsunami Glass Ind. Ltd., Osaka, Japan), air dried, fixed in 4% paraformaldehyde/phosphate-buffered saline (PBS) for 10 minutes, permeabilized in 0.1% saponin/PBS for 10 minutes, blocked with 3% bovine serum albumin/PBS for 30 minutes, and stained with primary antibodies for 2 hours and then with the appropriate Alexa Fluorconjugated secondary antibodies for 1 hour. These staining procedures were performed at room temperature. The specimens were mounted with VECTASHIELD mounting medium (Vector Laboratories Inc., Burlingame, CA) and then visualized by confocal microscopy using a Leica TCS SP5 II laser scanning confocal microscope.
Statistical Analysis. Experiments were repeated at least three times, and the data are presented as mean 6 S.E.M. The p-values between two variables were calculated at a 95% confidence level using unpaired Student's t tests. The data were analyzed using Prism software (GraphPad Software, La Jolla, CA). (Fig. 1B) . The smaller band of Atp11c could be produced by caspasemediated cleavage . As reported previously, the liver function tests showed markedly elevated concentrations of total and direct bilirubin and total BAs and normal activity of GGT in the plasma of Atp11c emptyhive/Y mice (Siggs et al., 2011a) (Fig. 2E) .
Results

Expression of Atp11c in LPMs from
[ 3 H]E 2 17bG undergoes vectorial transport through OATPs/ Oatps and MRP2/Mrp2, which mediate the hepatic uptake of unconjugated BAs (Meier et al., 1997; van de Steeg et al., 2010) and biliary excretion of sulfated BA amidates and BA ethereal glucuronides (divalent) (Kuipers et al., 1988; Takikawa et al., 1991; Akita et al., 2001) 17bG into the hepatocytes from both mice was observed, but was markedly decreased in the presence of 100 mM unlabeled compounds (Fig. 3, A and B emptyhive/Y Mice. Consistent with the results of the in vitro uptake study using the isolated hepatocytes, analysis of LPMs by Western blot analysis showed a markedly decreased expression of the sinusoidal transporters responsible for BA uptake, Oatp1b2, Oatp1a4, and Ntcp in Atp11c emptyhive/Y mice (Fig. 4A) . Na 1 , K 1 -ATPase a1 subunit, another sinusoidal membrane protein, was unaffected in Atp11c emptyhive/Y mice, suggesting that the role of Atp11c in the maintenance of the expression of sinusoidal membrane proteins is relatively specific for Oatps and Ntcp. In contrast to the altered expression of sinusoidal transporters for BA uptake, the abundance of Bsep and Mrp2, both of which mediate biliary excretion of BAs across the CM, did not differ between mice. Together with the finding that (Fig. 4B) . However, this difference is unlikely to explain the markedly decreased expression of Oatp1b2 and Ntcp. The immunohistochemical analysis of liver frozen sections showed basolateral localization of Atp11c in hepatocytes (Fig.  4C) . The immunosignal was undetectable in specimens from Atp11c 1/Y mice.
Discussion
PFIC, a heterogeneous group of inherited autosomal recessive liver diseases, is attributed to the impaired transport of BAs across the CM of hepatocytes (Wang et al., 2002; Chen et al., 2004; Hayashi et al., 2005a; Paulusma et al., 2009 ). The causal gene of PFIC with the normal GGT is unidentifiable in about 30% of affected individuals (Davit-Spraul et al., 2010) . Atp11c mutant mice present with a similar phenotype to PFIC (Siggs et al., 2011a; Yabas et al., 2011 Yabas et al., , 2014 (Tables 2 and 3 ). This result can be explained by two observations: 1) the much lower expression of Oatps, including Oatp1b2 and Oatp1a4, which are sinusoidal transporters for the hepatic uptake of BAs and organic anions, and 2) the unaffected expression of Bsep and Mrp2, which are canalicular transporters for the biliary excretion of BAs, in Atp11c mutant mice compared with control mice (Fig. 4A) . Slco1a/1b cluster knockout mice exhibit hypercholanemia and hyperbilirubinemia because of compromised hepatic uptake of BAs and reuptake of conjugated bilirubin (van de Steeg et al., 2010) ; therefore, the reduced function of Oatps, but not of Bsep and Mrp2, is probably responsible for the hypercholanemia and hyperbilirubinemia observed in Atp11c mutant mice. This suggests that Atp11c may be a causal gene responsible for genetically undiagnosed cases of hypercholanemia and hyperbilirubinemia, such as in Rotor syndrome, without mutations in SLCO1B1 and SLCO1B3, but not for cases of PFIC.
OATPs mediate the hepatic uptake of a wide variety of structurally unrelated compounds, including clinically used drugs, such as 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins), angiotensin II receptor blockers (sartans), and angiotensin converting enzyme inhibitors, and thereby regulate their dispositions (Giacomini et al., 2010 (Giacomini et al., , 2013 . Genetic polymorphisms and drug-drug interactions that emptyhive/Y (black) mice was measured at 37°C in the absence (circles) or presence (squares) of 100 mM unlabeled compounds. The uptake amount per minute of [ significantly alter the function of OATPs affect the systemic exposure of their substrates, which causes increased pharmacological effects and adverse reactions, such as statin-induced myotoxicity (Link et al., 2008; Giacomini et al., 2010 Giacomini et al., , 2013 . Therefore, the results of the current study imply implications of Atp11c in drug disposition and thereby in its pharmacological and adverse effects. To our knowledge, this is the first report to suggest the association of P4-ATPases with disposition, pharmacological action, and toxicity of drugs. Several coding SNPs in ATP11C have been reported in the dbSNP database hosted by National Center for Biotechnology Information (NCBI). If these influences on function and expression of ATP11C are confirmed, ATP11C should receive more attention in the attempt to improve drug development and to overcome interindividual variations in medical therapy.
It remains unknown why the basolateral expression of Oatps and Ntcp is markedly reduced in Atp11c mutant mice. One possible mechanism is that Atp11c functions to maintain the well organized aminophospholipid asymmetry of the basolateral membrane, as is the case of ATP8B1/Atp8b1, which translocates phosphatidylserine from the outer leaflet to the inner leaflet at the hepatocanalicular membrane and thereby contributes to making it a rigid, liquid-ordered membrane (Paulusma et al., 2006 (Paulusma et al., , 2008 . Disruption of membrane fluidity because of defective Atp11c function might alter the dynamics of Oatps and Ntcp on the basolateral membrane, which may destabilize and facilitate their degradation and thereby reduce the expression of these transporters on the basolateral membrane. This hypothesis is supported by the basolateral localization of Atp11c in hepatocytes (Fig. 4C) and its function at the plasma membrane of cultured cells in the translocation of aminophospholipids into the inner leaflet (Yabas et al., 2011; Segawa et al., 2014; Takatsu et al., 2014) . Alternatively, Atp11c may affect the trafficking of transport vesicles containing Oatps and Ntcp to the basolateral membrane, as has been shown for Atp8a1 and P4-ATPases of Saccharomyces cerevisiae and Caenorhabditis elegans (Liu et al., 2008; Chen et al., 2010; Lee et al., 2015) . It has been suggested that these P4-ATPases form the membrane curvature and/or recruit membrane fission protein through the unidirectional transport of phospholipids from the luminal leaflet to the cytosolic leaflet in the organelles in which they localize, which helps to generate transport vesicles. Although Atp11c localizes predominantly on the plasma membrane in HeLa cells (Takatsu et al., 2011) , its minor distribution to other organelles, such as the Golgi apparatus and endosome in hepatocytes may influence the budding of transport vesicles containing Oatps and Ntcp to the basolateral membrane. Future research to identify the intracellular localization of Atp11c in hepatocytes will provide further insight into the role of Atp11c in the regulation of the basolateral expression of Oatps and Ntcp.
In conclusion, we have demonstrated that Atp11c is indispensable to maintaining the appropriate expression level of Oatps and is thereby involved in the hepatic uptake of BAs and organic anions, including conjugated bilirubin, across the sinusoidal membrane. These results suggest that ATP11c is a candidate gene that may be responsible for genetically undiagnosed cases of hypercholanemia and hyperbilirubinemia, but not of PFIC. Our results are consistent with the recent preliminary results of Naik et al., which suggested Oatp1b2 contributes to hyperbilirubinemia and hypercholanema in Atp11c mutant mice (Naik et al., 2015) . ATP11C/Atp11c may influence the disposition, pharmacological effect, and toxicity of drugs because Oatps/Oatps mediate the hepatic uptake of many drugs and consequently regulate their systemic exposure. Future research with global analysis to identify membrane proteins whose expression is affected by ATP11C/Atp11c provides further insight into the regulatory mechanism of the sinusoidal membrane proteins by ATP11C/ Atp11c and expands the understanding of the physiologic and pharmacological importance of ATP11C/Atp11c.
